Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCB-1033
- Development stage
- Phase 2
- Lead developer
- Clover Biopharmaceuticals
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**SCB-1033** is Clover Biopharmaceuticals' investigational fixed-dose recombinant protein subunit vaccine designed to prevent respiratory disease caused by respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3. The vaccine uses prefusion-stabilized fusion-protein trimer antigens produced with Clover's Trimer-Tag platform to induce protective neutralizing immune responses against the three respiratory viruses. It is being evaluated in older adults and is in Phase 2 clinical development. ([cloverbiopharma.com](https://www.cloverbiopharma.com/science%26technology/ourpipeline.html))
- Other names
- RSV + hMPV + PIV3 respiratory combination vaccine candidateRSV-hMPV-PIV3 combination vaccine candidateRSV-hMPV-PIV-3 combination vaccine candidateRSV-hMPV-PIV 3 combination vaccine candidateRSV-hMPV-PIV3 protein subunit vaccine candidateRSV-hMPV-PIV-3 protein subunit vaccine candidateRSV-hMPV-PIV 3 protein subunit vaccine candidate
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)HMPV F (Human metapneumovirus fusion protein)RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on SCB-1033.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCB-1033.